Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases

Gurtej S. Cheema, Viktor Roschke, David M. Hilbert, William Stohl

Research output: Contribution to journalArticle

640 Citations (Scopus)

Abstract

Objective. To determine whether serum levels of B lymphocyte stimulator (BLyS) are elevated in patients with systemic immune-based rheumatic diseases and correlate with serum Ig levels and/or autoantibody titers. Methods. Sera from 185 patients with various systemic immune-based rheumatic diseases (95 with systemic lupus erythematosus [SLE], 67 with rheumatoid arthritis [RA], 23 with other diagnoses) were assayed for BLyS and Ig. In 7 patients who required arthrocentesis of a swollen knee, coincident serum and synovial fluid samples were assayed for BLyS. Medical charts were retrospectively reviewed for elevated autoantibody titers and proteinuria within a 1-month period before or after collection of sera for BLyS and Ig determination. Sera concurrently collected from 48 normal healthy subjects served as controls. Results. Serum BLyS levels were elevated in 38 of 185 patients (21%) and correlated significantly with serum IgG levels. Serum BLyS levels did not correlate with the patients' age, sex, race, or medications, but correlated positively with anti-double-stranded DNA antibody titers among SLE patients and with rheumatoid factor titers among seropositive RA patients. In contrast, serum BLyS levels correlated inversely with nephrotic-range proteinuria among SLE patients. In every case tested, BLyS levels in clinically inflamed synovial fluids were greater than those in simultaneously obtained sera. Conclusion. BLyS may be an important factor in driving polyclonal hypergammaglobulinemia and elevated autoantibody titers in patients with systemic immune-based rheumatic diseases. Local production of BLyS in the joints may contribute to joint pathology. Patients with elevated serum BLyS levels may be ideal candidates for therapeutic targeting of BLyS.

Original languageEnglish (US)
Pages (from-to)1313-1319
Number of pages7
JournalArthritis and Rheumatism
Volume44
Issue number6
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

B-Cell Activating Factor
Rheumatic Diseases
Serum
Systemic Lupus Erythematosus
Autoantibodies
Synovial Fluid
Proteinuria
Rheumatoid Arthritis
Joints
Hypergammaglobulinemia
Rheumatoid Factor

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. / Cheema, Gurtej S.; Roschke, Viktor; Hilbert, David M.; Stohl, William.

In: Arthritis and Rheumatism, Vol. 44, No. 6, 2001, p. 1313-1319.

Research output: Contribution to journalArticle

Cheema, Gurtej S. ; Roschke, Viktor ; Hilbert, David M. ; Stohl, William. / Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. In: Arthritis and Rheumatism. 2001 ; Vol. 44, No. 6. pp. 1313-1319.
@article{a99128a11f414244822787d47aa9b65e,
title = "Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases",
abstract = "Objective. To determine whether serum levels of B lymphocyte stimulator (BLyS) are elevated in patients with systemic immune-based rheumatic diseases and correlate with serum Ig levels and/or autoantibody titers. Methods. Sera from 185 patients with various systemic immune-based rheumatic diseases (95 with systemic lupus erythematosus [SLE], 67 with rheumatoid arthritis [RA], 23 with other diagnoses) were assayed for BLyS and Ig. In 7 patients who required arthrocentesis of a swollen knee, coincident serum and synovial fluid samples were assayed for BLyS. Medical charts were retrospectively reviewed for elevated autoantibody titers and proteinuria within a 1-month period before or after collection of sera for BLyS and Ig determination. Sera concurrently collected from 48 normal healthy subjects served as controls. Results. Serum BLyS levels were elevated in 38 of 185 patients (21{\%}) and correlated significantly with serum IgG levels. Serum BLyS levels did not correlate with the patients' age, sex, race, or medications, but correlated positively with anti-double-stranded DNA antibody titers among SLE patients and with rheumatoid factor titers among seropositive RA patients. In contrast, serum BLyS levels correlated inversely with nephrotic-range proteinuria among SLE patients. In every case tested, BLyS levels in clinically inflamed synovial fluids were greater than those in simultaneously obtained sera. Conclusion. BLyS may be an important factor in driving polyclonal hypergammaglobulinemia and elevated autoantibody titers in patients with systemic immune-based rheumatic diseases. Local production of BLyS in the joints may contribute to joint pathology. Patients with elevated serum BLyS levels may be ideal candidates for therapeutic targeting of BLyS.",
author = "Cheema, {Gurtej S.} and Viktor Roschke and Hilbert, {David M.} and William Stohl",
year = "2001",
doi = "10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S",
language = "English (US)",
volume = "44",
pages = "1313--1319",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases

AU - Cheema, Gurtej S.

AU - Roschke, Viktor

AU - Hilbert, David M.

AU - Stohl, William

PY - 2001

Y1 - 2001

N2 - Objective. To determine whether serum levels of B lymphocyte stimulator (BLyS) are elevated in patients with systemic immune-based rheumatic diseases and correlate with serum Ig levels and/or autoantibody titers. Methods. Sera from 185 patients with various systemic immune-based rheumatic diseases (95 with systemic lupus erythematosus [SLE], 67 with rheumatoid arthritis [RA], 23 with other diagnoses) were assayed for BLyS and Ig. In 7 patients who required arthrocentesis of a swollen knee, coincident serum and synovial fluid samples were assayed for BLyS. Medical charts were retrospectively reviewed for elevated autoantibody titers and proteinuria within a 1-month period before or after collection of sera for BLyS and Ig determination. Sera concurrently collected from 48 normal healthy subjects served as controls. Results. Serum BLyS levels were elevated in 38 of 185 patients (21%) and correlated significantly with serum IgG levels. Serum BLyS levels did not correlate with the patients' age, sex, race, or medications, but correlated positively with anti-double-stranded DNA antibody titers among SLE patients and with rheumatoid factor titers among seropositive RA patients. In contrast, serum BLyS levels correlated inversely with nephrotic-range proteinuria among SLE patients. In every case tested, BLyS levels in clinically inflamed synovial fluids were greater than those in simultaneously obtained sera. Conclusion. BLyS may be an important factor in driving polyclonal hypergammaglobulinemia and elevated autoantibody titers in patients with systemic immune-based rheumatic diseases. Local production of BLyS in the joints may contribute to joint pathology. Patients with elevated serum BLyS levels may be ideal candidates for therapeutic targeting of BLyS.

AB - Objective. To determine whether serum levels of B lymphocyte stimulator (BLyS) are elevated in patients with systemic immune-based rheumatic diseases and correlate with serum Ig levels and/or autoantibody titers. Methods. Sera from 185 patients with various systemic immune-based rheumatic diseases (95 with systemic lupus erythematosus [SLE], 67 with rheumatoid arthritis [RA], 23 with other diagnoses) were assayed for BLyS and Ig. In 7 patients who required arthrocentesis of a swollen knee, coincident serum and synovial fluid samples were assayed for BLyS. Medical charts were retrospectively reviewed for elevated autoantibody titers and proteinuria within a 1-month period before or after collection of sera for BLyS and Ig determination. Sera concurrently collected from 48 normal healthy subjects served as controls. Results. Serum BLyS levels were elevated in 38 of 185 patients (21%) and correlated significantly with serum IgG levels. Serum BLyS levels did not correlate with the patients' age, sex, race, or medications, but correlated positively with anti-double-stranded DNA antibody titers among SLE patients and with rheumatoid factor titers among seropositive RA patients. In contrast, serum BLyS levels correlated inversely with nephrotic-range proteinuria among SLE patients. In every case tested, BLyS levels in clinically inflamed synovial fluids were greater than those in simultaneously obtained sera. Conclusion. BLyS may be an important factor in driving polyclonal hypergammaglobulinemia and elevated autoantibody titers in patients with systemic immune-based rheumatic diseases. Local production of BLyS in the joints may contribute to joint pathology. Patients with elevated serum BLyS levels may be ideal candidates for therapeutic targeting of BLyS.

UR - http://www.scopus.com/inward/record.url?scp=0034972257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034972257&partnerID=8YFLogxK

U2 - 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S

DO - 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S

M3 - Article

C2 - 11407690

AN - SCOPUS:0034972257

VL - 44

SP - 1313

EP - 1319

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 6

ER -